Forsteo ® (teriparatid)

För fullständig produktresumé för Forsteo® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Forsteo® (teriparatid): Farmakokinetiska egenskaper

Teriparatid absorberas snabbt från injektionsstället, har en halveringstid på cirka 1 timme och är odetekterbar i blodet inom 3 timmar.

Further information on Pharmacokinetic Properties

Absorption and Distribution

The half-life of Forsteo is approximately 1 hour when administered subcutaneously, which reflects the time required for absorption from the injection site. 1

Teriparatide is rapidly and extensively absorbed following subcutaneous injection, with a maximum serum concentration at approximately 30 minutes.2,3

The volume of distribution is approximately 1.7 L/kg.1

Biotransformation and Elimination

No metabolism or excretion studies have been performed with Forsteo but the peripheral metabolism of parathyroid hormone is believed to occur predominantly in liver and kidney.1

Forsteo is eliminated through hepatic and extra-hepatic clearance (approximately 62 L/hr in women and 94 L/hr in men).1

Teriparatide is rapidly eliminated with a decrease to nonquantifiable concentrations within 3 hours of the dose.3

References

1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485-492. http://dx.doi.org/10.1007/s00223-010-9424-6

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Datum fӧr senaste ӧversyn 2019 M11 11

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss